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Abstract
Recent data have redefined the concept of inflammation as a critical component of tumor
progression. However, there has been little development on cases where inflammation on or near
a wound and a tumor exist simultaneously. Therefore, this pilot study aims to observe the impact
of a wound on a tumor, to build a new mouse tumor model with a manufactured surgical wound
representing acute inflammation, and to evaluate the relationship between acute inflammation or
wound healing and the process of tumor growth. We focus on the two phases that are present
when acute inflammation influences tumor. In the early phase, inhibitory effects are present. The
process that produces these effects is the functional reaction of IFN-γ secretions from a wound
inflammation. In the latter phase, the inhibited tumor is made resistant to IFN-γ through the release
of TGF-β to balance the inflammatory factor effect on the tumor cells. A pair of cytokines IFN-γ/
TGF-β established a new balance to protect the tumor from the interference effect of the
inflammation. The tumor was made resistant to IFN-γ through the release of TGF-β to balance the
inflammatory effect on the tumor cells. This balance mechanism that occurred in the tumor cells
increased proliferation and invasion. In vitro and in vivo experiments have confirmed a new view of
clinical surgery that will provide more detailed information on the evaluation of tumors after
surgery. This study also provides a better understanding of the relationship between tumor and
inflammation, as well as tumor cell attacks on inflammatory factors.
Introduction
As early as 1863, Virchow first postulated that cancer orig-
inates at the sites of chronic inflammation. This is partly
based on his hypothesis that some classes of irritants caus-
ing inflammation also enhance cell proliferation [1]. In
the past decades, scientists have made considerable
progress in research on the relationship between cancer
and inflammation [1,2]. Inflammation is a part of the
host's response to either internal or external environmen-
tal stimuli. This response serves to counteract the trauma
incurred by these stimuli against the host. This can be
pyrogenic, as indicated by fever. Acute inflammation or
fever manifested for a short period has a therapeutic con-
sequence [3]. Under normal circumstances, the wound
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healing process is considered an acute inflammation, like
surgical wound healing. This process involves the classic
model of inflammatory response, including the forma-
tion of granulation tissue, leukocyte infiltration, angio-
genesis factor, and cytokines network [4]. During acute
inflammation, the emergence of cell proliferation, angio-
genesis, and reconstruction of the organization are very
similar to tumor growth and progression. However, since
there are two different consequences, the former is limited
and controlled, while the latter is unlimited and irregular
[2,5].
Tumor patients are characterized with an abnormal
immune function, with majority of the patients having
low immunity. Some have enforced incomplete tumor
resection where the surgery wound also heals normally.
This is a common clinical phenomenon. In tumor cells
that can secrete a strong cytokines pattern, the residual
tumor cells particularly release a large amount of
cytokines after incomplete resection, which stimulate the
surrounding tissue under repair, thus speeding up the
wound healing process. This involves the vascular
endothelial growth factor (VEGF), epidermal growth fac-
tor (EGF), basic fibroblast growth factor (bFGF), and
other cytokines [3,6]. This makes the question on whether
the influence of surgery wounds on tumor cells depresses
or promotes proliferation in tumor cells, interesting.
To evaluate the relationship between acute inflammation
or wound healing and tumor growth, this study utilizes a
mouse tumor model with a manufactured surgical
wound. The model is capable of building a representation
of acute inflammation. Present in this model are the
inhibitory effects on tumor growth of acute inflammation
in the early stage, which is the functional reaction of IFN-
γ due to wound inflammation. In the latter stage, the role
of the tumor is to resist IFN-γ by releasing TGF-β to bal-
ance the inflammatory factor effect on the tumor cells.
Similar to real situations, a pair of cytokines IFN-γ/TGF-β
established a new balance to protect the tumor from the
interference factor of inflammation. Likewise, a new
immune escape mechanism in the tumor cells occurred
because of increased access to cell proliferation. Our in
vitro and in vivo experiments confirmed a new view of
clinical surgery that will provide more detailed informa-
tion to evaluate tumors after surgery. The study also offers
a better understanding of the relationship between tumor




Cells: Mouse melanoma cell-line B16F10 was supplied by
the Department of Cell Biology, Huanhu Hospital, Tian-
jin, People's Republic of China. The cell was cultured in
RPMI1640 medium (Hyclone) containing 10% fetal
bovine serum (FBS: Gibco), 50 units/ml penicillin, and 50
μg/ml streptomycin (Gibco). In all the experiments, the
cell was maintained in 100 mm culture dishes (Costar) at
37°C in humidified 5% CO2/95% air atmosphere.
Animals: female six-week old, 18~22 g C57/BL mice were
purchased from the Animal Center Academy of Military
Medical Science (License: SCXK [Jin] 2004-0001; Beijing,
China). They were brought to the Animal Centre of Tian-
jin Medical University one week before the experiment
and were bred under the specific pathogen-free (SPF) con-
ditions.
Proliferation Assay
(Sulforhodamine-B, Sigma) (SRB) assay: Exponentially
growing B16F10 melanoma cell lines were plated at 5 ×
104 cells/ml in flat-bottomed 24-well plates (Costar) in 1
mL of complete RPMI 1640 medium containing 1% fetal
bovine serum. The tumor cells were then incubated for 8
h, 16 h, 24 h, 32 h, 40 h, and 48 h in various concentra-
tions of cytokines at a total volume of 1 ml. The final con-
centration of TGF-β (Peptech) was 5 ng/ml, while that of
IFN-γ (Peptech) was 10 ng/ml. The solution without
cytokines was assigned as the control group. After incuba-
tion for a specific number of hours at 37°C in 5% CO2,
fixing, and staining by SRB, the optical densities and per-
centage viability were then determined by absorption at
540 nm (A540).
Invasion and Wound Healing Assay
Migration assay was performed using Transwell cell cul-
ture inserts with 8 μm porosity polyethylene teraphthalate
filters (Invitrogen). Briefly, confluent tumor cells were
trypsinized and plated onto the upper Matrigel-coated
insert and were allowed to attach to the membrane for 1
h. Cytokines were then added into the free-FBS media in
the upper inserts, free-cytokines, and free-FBS media as
controls. The lower inserts used 20% FBS media as chem-
oattractant both in the cytokines groups and the controls.
Cells were allowed to migrate for 24 h. The upper surface
of the membrane was then wiped to remove nonmigra-
tory cells. The cells that invaded through the Matrigel and
adhered to the bottom of the membrane were stained
with crystal violet solution. The cell-associated dye was
eluted with 10% acetic acid, and its absorbance at 595 nm
was determined. Each experiment was done in triplicate,
and the mean values, mean ± SE were presented. Wound
healing assays were done with six-well chambers. Cell
motility was assessed by measuring the movement of the
cells into a scarped, acellular area created by a 200 μL
pipette tube (time 0). The speed of the wound closure was
monitored after 12 h, and the ratio of the distance of the
wound in relation to 0 h was measured. Each experimentJournal of Experimental & Clinical Cancer Research 2009, 28:23 http://www.jeccr.com/content/28/1/23
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was also done in triplicate, and the mean values, mean ±
SE were presented.
Mouse Tumor with Wound Model
About 107/mL B16F10 melanoma cell suspension was
injected into the left groin area of the mice in 0.2 ml for
each mouse. Thirth-one mice were randomly divided into
the wound group (18 mice) and the control group (13
mice). Ten days after the tumor cells were engrafted, the
tumor masses were detected. When the tumor grew to 1
cm3, a 2~3 cm2 wound was built on the opposite side of a
bodies in the wound group. The mice in the control group
were treated without wounds. The mice were sacrificed by
cervical decapitation on the seventh and 11th days follow-
ing continuous wound treatment.
Mouse Tumor Model with Cytokines injection
A volume of 0.2 ml of about 107/mL B16F10 melanoma
cell suspension was injected into the left groin area of the
mice. Sixteen mice were randomly divided into the
wound group (8 mice) and the control group (8 mice).
When the tumor of the mice in the wound group grew to
5 cm3, they were injected with IFN-γ (500 pg/g) through
the tail-vein every 3 days. The mice in the control group
were only treated with 0.9% NaCl solution. Then the mice
were sacrificed by cervical decapitation on the 7th and
11th days following continuous wound treatment.
Gelatin Zymography
Gelatin zymography was used to examine the levels of
matrix metalloproteinases-2 (MMP-2) and MMP-9 activ-
ity after the cells were treated with cytokines. To change all
media into free-FBS conditioned media and replace the
treated cells with cytokines after 24 h, the free-FBS condi-
tioned media were used as a control. All media were col-
lected and subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) using
0.01% w/v gelatin containing 10% polyacrylamide gel.
After electrophoresis, the gels were equilibrated in 50 mM
Tris-HCl (pH 7.5) with 2.5% Triton X-100 for 30 min at
room temperature. They were then incubated in 50 mM
Tris-HCl (pH 7.5), 10 mM CaCl2, 150 mM NaCl, 1 mM
ZnCl2 and 0.02% NaN3 for 20 h at 37°C. The gels were
stained with Coomassie R250 and destained until the
wash became clear and the cleared zones associated with
MMP activity were apparent. The zymogram was digitized
and the amount of clearing associated with MMP-2 and
MMP-9 activity was determined using the Gene Genius
Super system. The values were calculated using densitom-
etry. Samples of the animals' tumor were lysed by 2% SDS
in liquid nitrogen, and the lysates were collected and cen-
trifuged to obtain soluble cell extract.
Immunohistochemical Staining Methods
Four micrometer-thick sections were mounted on poly-L-
lysine-coated slides. Slides were deparaffinized in xylene.
Endogenous peroxidase (POD) activity was blocked with
3% hydrogen peroxide in 50% methanol for 10 min at
room temperature. Sections were rehydrated in alcohol,
washed with phosphate-buffered saline (PBS) and then
pretreated with citrate buffer (0.01 M citric acid, pH 6.0)
for 20 min at 95°C in a microwave oven. After nonspecific
binding sites were blocked by exposing them to 10% nor-
mal goat serum in PBS for 20 min at 37°C, sections were
incubated overnight at 4°C with a series of antibodies
(Santa Cruz Biotechnology, dilution 1:100). Following
this incubation, the sections were rinsed with PBS and
incubated with biotinylated goat anti-mouse IgG for 20
min at 37°C. The slides were then incubated with 3, 3'-
diaminobenzidine chromogen for 5–10 min at room tem-
perature and washed with distilled water. Finally, sections
were slightly counterstained with hematoxylin for 1 min
followed by dehydration and coverslip mounting. PBS
was utilized in place of the primary antibodies for the neg-
ative control. The staining systems used in this study were
PicTure PV6000 (Zhongshan Chemical Co., Beijing,
China) and Elivision Plus (Zhongshan Chemical Co. Bei-
jing).
Enzyme-linked immunosorbent assay (ELISA) Analysis of 
the Levels of IFN-γ and TGF-β
The IFN-γ and TGF-β detection ELISA kit was used to
detect the concentration of IFN-γ and TGF-β in the mouse
model serum and the tumor lysate, in accordance with
operating manuals. The reaction between POD and ABTS
was photometrically determined using a microplate
reader at 405 nm.
Statistical Analysis
All data in the study were evaluated using SPSS11.5 (SPSS
Inc., USA). Differences were considered significant at val-
ues of p < 0.05. Significant results were marked with "*".
Results
Inflammation effect on the melanoma showed two phases: 
Inhibition and inhibition missing
To determine if inflammation has an inhibitory effect on
the melanoma cells, a wound mouse model was built.
When the tumor grew to a specific size, we created a
wound in the opposite side of the mouse's body. The
wound model was used to manufacture a full-body model
of acute inflammation in order to investigate the macro
effect between inflammation and tumors. The results
show a gradual reduction of tumor volume when the
wound was building; the tumor volume reached the min-
imum at day 7. After day 7, the inhibitory effect of the
wound (inflammation) on the tumor down-regulated
gradually. The tumor volume of the inflammatory groupJournal of Experimental & Clinical Cancer Research 2009, 28:23 http://www.jeccr.com/content/28/1/23
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at day 11 was almost the same as the control group at day
13. This is even higher than the average tumor volume.
The tumor growth curve showed two phases: the early
phase (before day 7, the inhibition phase) and the latter
phase (after day 7 and marked in day 11, the inhibition
missing phase). The latter phase presented an increasing
proliferation of tumors. (Figure 1A)
The cross-section of the tumor showed that the tumor
necrosis with hemorrhage occurred at different times and
groups. On day 7, the tumors in the wound group were
smaller than those in the control group, while the areas
with necrotic tissues were greater than those in the control
group. After 11 days, the tumor volume in the wound
group was increasing, but the necrotic areas in the cross-
section decreased in a faster rate than those in the control
group. The necrotic percentage after day 11 showed that
the tumor, through a mechanism to adapt to the wounds
caused by inflammation, induced necrosis which pro-
moted proliferation (Figure 1B). These results indicate
that in the early phase, the inflammation occurred, and
the inflammatory factors secreted into the blood indi-
rectly influenced the tumor and induced necrosis so that
the tumor regressed. In the latter phase, although inflam-
mation was still present, biological changes gave the
tumor the ability to resist inflammation, and even
enhanced the ability of the tumor cells to increase.
New balance in inflammation and melanoma: the lever 
roles of IFN-γ/TGF-β
To further observe and determine the other inflammatory
factors in the interaction between tumors and inflamma-
tion, we collected the serum samples used to screen the
cytokines. The results showed that the level of IFN-γ in the
serum for the wound group continued at high levels of
expression. High concentrations of IFN-γ were also
detected in the tumor tissue. IFN-γ is an inflammation fac-
tor mainly because of the secretions of the Th1 cells. It
inhibits tumor activity via the normal physiological proc-
ess for cell death [7,8]. We also conducted an analysis on
the other inflammatory factors in our experiment, such as
interleukin-1(IL-1), IL-4, IL-10, tumor necrosis factor-
α(TNF-α), and vascular endothelial growth factor-a
(VEGF-a) which were not observed as influential to the
tumor growth curve (data not shown). However, the
results show that IFN-γ's inflammatory factor has an
impact on tumor tissue, inhibits tumor growth, and
induces tumor cell apoptosis or necrosis.
Interestingly, after day 7, TGF-β increased in the tumors.
The TGF-β level before day 7 day was detected in the cate-
gory of low expression and secretion of tumor cells (Figure
2). Figure 2 shows that the tumor has to enhance the reg-
ulation of TGF-β to fight against IFN-γ. The role of TGF-β
has been demonstrated with the IFN-γ-induced inhibition
of tumor necrosis and persistence over a period, giving
tumor cells the ability to fight IFN-γ and thus resulting in
tumor cell growth.
Investigation of the antagonism between IFN-γ and TGF-β 
in vitro
We investigated whether TGF-β can promote tumor cell
proliferation or induced apoptosis, and whether IFN-γ can
inhibit this tumor cell proliferation. In addition, we exam-
ined whether TGF-β can fight the inhibition effect of IFN-
γ in the tumor cell when TGF-β and IFN-γ were adminis-
tered at the same time in (the T and I group). A similar
growth curve resulted for both the T and I group and the
control group despite (no cytokines) were applied to the
latter, providing growth opportunities for the cells under
IFN-γ treatment. A morphology test also shows that when
TGF-β induced a rapid proliferation of cells, the cells pre-
sented a spindle-like shape. On the other hand, the IFN-γ
group presented a reduction tendency on cell adhesion,
with the shape of the cells being suspended or polygonal.
When administered with TGF-β and IFN-γ at the same
time, the cells returned to their normal B16 cell shape
(Figure 3A and 3B).
The results of the wound healing assay also showed that
TGF-β confronting IFN-γ can promote cell migration.
Treating cells with IFN-γ alone inhibited cell migration.
Further experiments showed that IFN-γ can inhibit cell
migration and invasion. This result was obtained through
Matrigel as analyzed by Transwell invasion assay. TGF-β
has the opposite effect on cells and may also possess the
characteristics that inhibit IFN-γ activity. These lead to cell
migration and invasion (Figure 3C and 3D).
The lever of IFN-γ/TGF-β plays a new role in the activity of 
melanoma invasion
To verify whether TGF-β and IFN-γ can enhance
melanoma cell invasion, gelatin zymography assay was
used. In the in vitro analysis, IFN-γ can reduce the activity
of MMP-2 and MMP-9, which are the key modulators of
tumor invasion. On the other hand, TGF-β can enhance
the activity of both MMP-2 and MMP-9. At the same time,
TGF-β confronted IFN-γ to recover the activity of MMPs,
and increased the activity of MMP-2 and MMP-9 in the T
and I group. In vivo animal experiments also showed that
there are significant features on day 7, as the wound group
had a significantly lower MMP-2 and MMP-9 activity as
compared to the control group, from 30% to 50%, respec-
tively. By day 11, there was no significant difference in the
activity of MMP-2 and MMP-9 between the wound group
and the control group (Figure 4).
Immunohistochemistry analysis showed that the TGF-β
positive cells in the wound and the control groups at day
7 presented weak expression; on day 11, the wound groupJournal of Experimental & Clinical Cancer Research 2009, 28:23 http://www.jeccr.com/content/28/1/23
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Figure 1 (see legend on next page)Journal of Experimental & Clinical Cancer Research 2009, 28:23 http://www.jeccr.com/content/28/1/23
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presented significantly strong expression of positive cells
higher than the control group. The positive cells of MMP-
2 and MMP-9 show the same tendency from the results in
the zymography. However, when the TGF-β up-regulated
the expression, the activity of the state of MMP-2 and
MMP-9 is restored to inhibiting the highest expression,
which are similar to in vitro results. Collagen IV (COL IV)
is an important extracellular matrix, as tumor cells were
used to build the early vascular structures, and play
important roles in tumor growth, angiogenesis, as well as
cell invasion and metastasis [9,10]. We analyzed COL IV
on days 7 and 11. The percentage of positive cells in the
wound group found in day 7 also had a lower expression
compared with the control group. However, in day 11, the
positive cells had similar results with the control group.
This shows that with both MMPs and extracellular matrix
plasticity, inflammation will continue to dampen
demand in the early phase, and reach the latter phase, as
cytokines such as TGF-β play new roles on tumor cells to
escape the shackles of inflammatory factors, access to
growth, and progression (Figure 5).
Investigation of the antagonism between IFN-γ and TGF-β 
by IFN-γ injection model in vivo
To investigate the process in which IFN-γ plays an impor-
tant role in the process of wound inhibition on tumor, a
validation experiment was done. We injected IFN-γ into
the tail-vein (injection group) to mimic the inflammatory
factors from the wound. The results show a similar effect
on both the wound group and the injection group. The
tumor growth curve showed two phases similar to the
curve of the wound group: the inhibition phase (days 5 to
9) and the inhibition missing phase (after day 9). In the
inhibition phase, there are no differences on the level of
TGF-β between the injection group and the control group.
However, in the inhibition missing phase, the level of
TGF-β increased significantly both in the serum and the
tumor of the injection group as compared to the control
group (Figure 6A).
The activity of MMP-2 and MMP-9 in the tumor tissue was
also detected by the gelatin zymography assay. In the inhi-
bition phase, IFN-γ slowed down the activity of MMP-2
and MMP-9, which was not observed in the control group.
On the other hand, in the inhibition missing phase, the
TGF-β expression was high, which enhanced the activity
of both MMP-2 and MMP-9 to confront the IFN-γ in the
IFN-γ injection group. These findings were not observed
in the control group (Figure 6B).
Discussion
To understand the role of inflammation in cancer evolu-
tion, it is important to understand the nature of inflam-
mation and how it contributes to physiological and
pathological processes such as wound healing and infec-
tion. While this phenomenon has been discussed for
more than 100 years, recent data have redefined the con-
cept of inflammation as a critical component of tumor
progression. Many types of cancer arise from inflamma-
tion [1-3,11-13]. While we are particularly concerned with
inflammation promoting the formation of tumors, it
should be noted that inflammation, especially in the
wound healing process, has many similarities as well as
differences with tumor formation. First, the inflammation
in the process of wound healing involves the formation of
granulation tissues, and the stromal cells of the compo-
nents need to be built. Likewise, it involves the process of
angiogenesis. Both the formation of granulation tissues
and angiogenesis are similar to the formation of tumor
stroma [14], as both of them have similar existence in the
cytokines network [15]. Second, wound healing is con-
trolled and limited. However, we found that the tumor
was uncontrollable, especially in cell proliferation and
angiogenesis [1,2,16-18]. In the initial stages of inflam-
mation, the body's normal regulatory mechanisms con-
trol the wound-healing process and tissue growth. This
normal regulatory mechanism does not exist in a tumor.
When the tumor and wound are in one body, the inflam-
mation of the wound interacts with the tumor. The inter-
action depends on the distance between them. If the
A wound model was built in C57BL/B16 tumor-bearing mouse to determine the influence on melanoma by inflammation Figure 1 (see previous page)
A wound model was built in C57BL/B16 tumor-bearing mouse to determine the influence on melanoma by 
inflammation. When the tumor grew to 0.5 cm3, we created a wound beyond the tumor in the opposite site of the mouse's 
body. A.) The results show gradual reduction of the tumor volume when the wound was building; the tumor volume reached 
the minimum at day 7 (shown in black box, p < 0.01). After day 7, the tumor inhibitory effect of the wound (inflammation) 
weakened gradually. On about day 11 of the inflammatory group compared with the control group, tumor volume almost as 
same as the control group at day 13 (shown in black box, p > 0.05). B.) The cross-section of the tumor showed that the tumor 
necrosis with hemorrhage occurred in different proportions of times and groups. On day 7, the group wound tumors were 
smaller than the control group, and the area with necrotic tissue is greater than the control group (p < 0.01). After 11 days, 
the tumor volume in the wound group was increased, but in the cross-section area of necrotic tissue rather than in the control 
group (p > 0.05). The necrotic percentage after day 11 showed the tumor through a mechanism to adapt the wounds caused 
by inflammation induced necrosis, promoted the emergence of proliferation.Journal of Experimental & Clinical Cancer Research 2009, 28:23 http://www.jeccr.com/content/28/1/23
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To further observe and determine the inflammatory factors in the interaction between tumor and inflammation, results  showed that: A.) the level of IFN-γ in the serum in the wound group continued a high level of expression (day 7 p < 0.01, day  11 p < 0.01); B.) in tumor tissue also detected high concentrations compared with the control group (day 7 p < 0.01, day 11 p  < 0.01) Figure 2
To further observe and determine the inflammatory factors in the interaction between tumor and inflamma-
tion, results showed that: A.) the level of IFN-γ in the serum in the wound group continued a high level of 
expression (day 7 p < 0.01, day 11 p < 0.01); B.) in tumor tissue also detected high concentrations compared 
with the control group (day 7 p < 0.01, day 11 p < 0.01). Interestingly, at the 11th day, the tumor with the TGF-β 
increased, the result is that: C.) high levels of TGF-β can also be detected in the serum (day 7 p > 0.05, day 11 p < 0.01); D.) 
the same change in tumor (day 7 p > 0.05, day 11 p < 0.01). The TGF-β level before day 7 is not clear in terms of the present 
low of expression and secretion of tumor cells. That showed that at this time, the tumor does not have to go through the reg-
ulation of TGF-β to go against the ability of IFN-γ. When the IFN-γ-induces inhibition of tumor necrosis and persistence over a 
period, the role of TGF-β has been demonstrated, giving the tumor cells the ability to fight against the IFN-γ, so that the tumor 
cells could grow.Journal of Experimental & Clinical Cancer Research 2009, 28:23 http://www.jeccr.com/content/28/1/23
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To investigate the cells deal with cytokines in vitro Figure 3
To investigate the cells deal with cytokines in vitro. A-B.) Morphology shows that TGF-β induced a rapid proliferation 
of cells, and cells presented a spindle-like shape. The IFN-γ group presented a reduction tendency on cell adhesion, the shape 
of cells present suspended or polygonal, lose normal B16 cells morphousorm. When given TGF-β and IFN-γ at the same time, 
cells returned to normal B16 cell shape, and cells also grew. C.) The results by wound healing assay showed that TGF-β con-
fronting IFN-γ can promote migration. To treat cells only by IFN-γ inhibited cells migration. D.) Based on the Transwell inva-
sion assay, IFN can inhibit cell migration, and inhibit cell invasion through Matrigel, and TGF-β has the opposite effect on cells 
to IFN-γ, and may have also an activity for inhibiting the IFN-γ activity, so that the cells migrate and invade.Journal of Experimental & Clinical Cancer Research 2009, 28:23 http://www.jeccr.com/content/28/1/23
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To verify whether TGF-β and IFN-γ can enhance melanoma cells invasion by gelatin zymography assay analyzed in vitro and in  vivo Figure 4
To verify whether TGF-β and IFN-γ can enhance melanoma cells invasion by gelatin zymography assay ana-
lyzed in vitro and in vivo. A.) B16 cells treated by cytokines, show that IFN-γ can reduce the activity of MMP-2 and MMP-9, 
which are key modulators of tumor invasion. On the other hand, TGF-β can enhance the activity of both MMP-2 and MMP-9, 
giving TGF-β and IFN-γ. At the same time, TGF-β confronted IFN-γ to recover the activity of MMPs, and performed increasing 
activities on MMP-2 and MMP-9. B.) In vivo animal experiments also showed that there are significant features in day 7; the 
wound group had significantly lower activities of MMP-2 and MMP-9 compared with the control group from, 30% to 50%, 
respectively. By day 11, there was no significant difference in the activity of MMP-2 and MMP-9 between the wound groups and 
the control group. (*, p < 0.01)Journal of Experimental & Clinical Cancer Research 2009, 28:23 http://www.jeccr.com/content/28/1/23
Page 10 of 14
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Figure 5 (see legend on next page)Journal of Experimental & Clinical Cancer Research 2009, 28:23 http://www.jeccr.com/content/28/1/23
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tumor is far from the wound, the interaction is mainly
effected by the inflammatory factors of the serum. Inflam-
mation in the process of wound healing under the body's
normal regulation, which may be in the form of cytokines
or inflammatory factors in the serum delivered to the
tumor, is observed. On the other hand, tumor cells can
also transmit molecular signals to the region of the heal-
ing wound to affect the process of inflammation and
wound healing. For instance, although the immune sys-
tem in tumor patients after surgery is usually abnormal,
the surgery wound would still heal well. Furthermore, the
residual tumor tissue promotes wound repair and the
healing process. To investigate the interaction between the
tumor and the inflammatory process in wound healing,
we established a stab wound on tumor-bearing mice, and
expanded it everyday to ensure that wound healing
remains in the early stage.
Melanoma is a leading cause of cancer-related deaths
worldwide through the aggressive and complex ways of
angiogenesis [19-22]. Melanoma cells have a strong
cytokine-secreting ability and complex signal regulatory
networks [23,24]. The B16 melanoma cells came from the
C57BL mouse, which has a normal immune system [25].
We used this animal model to determine the interaction
between wound healing and cancer.
The first observation of our study is on the early stages of
the wound. The tumor growth slowed down significantly
until the wound was within the seven-day period of the
model. We named this the tumor inhibition phase. At this
phase, inflammatory factors played important roles in
interfering with tumor cell proliferation by blood circula-
tion. One of these factors is IFN-γ. Our data suggest that
the serum and tumor had high levels of IFN-γ. IFN-γ is
secreted from activated cells such as Th1 CD4+ T-helper
cells into the tumor microenvironment. This enhanced
antitumor immune responses and in turn induced the
activation of macrophage cytotoxic activity [7,26,27].
IFN-γ increased susceptibility to apoptosis through Fas
activators and cytotoxic chemotherapies in many cell
types, including melanoma and colorectal carcinoma [28-
30]. Through interactions with p53 and the inhibitor of
apoptosis, XIAP, the ISG product XAF1 may allow APO2L/
TRAIL to fully activate downstream caspases [31,32]. IFN-
γ can up-regulate tumor-associated antigens, carcinoem-
bryonic antigen, and TAG72 both in vitro and in vivo
[33]. IFNs can also inhibit angiogenesis by altering the
stimuli from tumor cells and by directly inhibiting
endothelial cells. Endothelial cells are inhibited in motil-
ity; they undergo coagulation necrosis in vitro, while the
inhibition of angiogenesis occurs in vivo within 24 hours
of tumor cell inoculation. Suppression of bFGF, also
known as FGF2, is correlated with reduced vascularization
and tumor growth [34]. The following are the reasons that
accounted for our results. First is the tendency of the
wound to release IFN-γ into the blood, transport it into
the tumor, inhibit tumor growth, and promote tumor
necrosis. The wound group was significantly affected as
shown by the reduced tumor volume. The cross-section
revealed a high percentage of necrosis.
Interestingly, the persistence of the wound after seven
days (the earlier phase) showed a weakened influence on
the tumor. The tumor volume began to increase gradually
as compared to that in the control group. This was fol-
lowed by the tumor size approaching or exceeding the size
of that in the control group. In other words, in the first
seven days after the wound secretes IFN-γ and the other
factors, the tumor cells were inhibited. After seven days,
no reduction in the level of IFN-γ was observed. This was
confirmed when TGF-β was tested in serum or tumor. The
trend was higher. As such, IFN-γ did not inhibit the tumor
cells. We named this the "inhibition missing" phase.
Perhaps a series of cytokines could explain the contradic-
tion of the inhibition missing phase. The cytokine TGF-β
was detected in the tumor tissue in the wound group after
day 7, and should have been released into blood circula-
tion which would likely restore the growth of the tumor
cells. To test whether TGF-β had contrary effects on IFN-γ,
an in vitro assay was done. This proved that TGF-β has
Based on wound model described above, the tumor sample's immunohistochemistry analysis showed that, the TGF-β positive  cells both in the wound group and the control group day 7 presented weak expression Figure 5 (see previous page)
Based on wound model described above, the tumor sample's immunohistochemistry analysis showed that, the 
TGF-β positive cells both in the wound group and the control group day 7 presented weak expression. On day 
11, the wound group presented significantly strong expression of positive cells higher than the control group. The positive cells 
of MMP-2 and MMP-9 show the same tendency as the results in the zymography, but when the TGF-β up-regulated expression, 
the activity of the state of MMP-2 and MMP-9 were restored from inhibiting to the highest expression. COL IV is an important 
extracellular matrix, and the percentage of positive cells in the wound group found on day 7 had a lower expression compared 
with the control group. However, in day 11, reflected in the control group with similar results, which show that both MMPs 
and extracellular matrix plasticity and inflammation will continue to dampen demand in the early phase, and reach to the latter 
phase. This is because the cytokines such as TGF-β, play new roles on tumor cells to escape the shackles of inflammatory fac-
tors, access to the growth, and progression. A.) The positive cells are stained in brown. B.) The positive percent of cells, p < 
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Determination of the effect of IFN-γ injection on the tumor via tail-vein to validate the IFN-γ released from the wound model Figure 6
Determination of the effect of IFN-γ injection on the tumor via tail-vein to validate the IFN-γ released from the 
wound model. A.) The tumor growth curves showing the double-phase in the IFN-γ injection group, the inhibition phase, and 
the inhibition missing phase. In the inhibition missing phase, the level of TGF-β increased significantly in the IFN-γ injection 
group as compared to that in the control (marked by *, p < 0.05). B.) The activity of MMP-2 and MMP-9 as detected by the gel-
atin zymography analysis showing the decrease in the inhibition phase of the IFN-γ injection group and the significant increase 
in the inhibition missing phase as compared to the control group (marked by *, p < 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:23 http://www.jeccr.com/content/28/1/23
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antagonism with IFN-γ, can resume the growth of tumor
cells, migration, and invasion; it can also lead to the situ-
ation wherein IFN-γ reduces the activity of the tumor cells'
MMPs. In this situation, the tumor cells restored growth
and invasion, and avoided the inhibition of IFN-γ. The
validation experiment in vivo also presented a similar
effect on the tumor by IFN-γ injection. The level of TGF-β
also increased significantly in the inhibition missing
phase. Furthermore, the activities of MMP-2 and MMP-9
were also enhanced in the inhibition missing phase as
compared to those in the inhibition phase.
TGF-β is an important mediator of tumor progression,
which likewise regulates cell proliferation, migration, and
invasion; it is an important cytokine involved in a variety
of biological processes [35,36]. We detected VEGF-a,
bFGF, and other cytokines both in the serum and tumor
tissue. However, only the expression of TGF-β up-regu-
lated in the "inhibition missing phase," and was posi-
tively correlated to an increase in tumor size. The in vitro
data proved that TGF-β can confront IFN-γ so that the
tumor cells can restore proliferation and migration, and
that it has the ability to resume invasion and the activity
of the MMPs. The validation data in vivo also showed sim-
ilar effect and phenotype. The IHC data also support this
conclusion, as well as point out that Col IV is likewise reg-
ulated by the TGF-β/IFN-γ level.
In conclusion, the study has proven that when the wound
and the tumor exist at the same time, there will be a new
balance between TGF-β and IFN-γ. The wound, through
the secretion of IFN-γ, interferes with the growth of the
tumor cells and inhibits the tumor for a short period.
Some tumor cells, through unknown mechanisms, use
TGF-β against the IFN-γ effect in the restoration of tumor
proliferation, invasion, and migration. As for the source of
TGF-β, we speculated that the tumor cells mainly came
from inflammatory factors such as IFN-γ adaptability to
up-regulated expression, or were derived from the interac-
tion between the tumor cells and the stromal cells. This
needs further research to be conclusive. However, this
study has proven that at least, in the interaction between
tumor and inflammation by wounds, the existence of a
new balance between TGF-β and IFN-γ not only contrib-
utes to the understanding of how tumor cells adapt to the
inflammatory factor, but also provides a new basis to ana-
lyze the effects of the inflammatory process on tumors.
This study also provides a reference to tumor surgery,
especially in post-operative residual tumor assessment.
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